Nuformix posts loss, continues Asian licensing talks

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Drug re-purposing specialist Nuformix posted a first-half loss as its revenue fell.

Pre-tax losses for the six months through September amounted to £0.48 million, compared to losses of £0.13 million year-on-year.

Revenue dropped to £0.20 million, down from £0.54 million.

Nuformix said it was continuing discussions with potential partners on licensing its lead asset, NXP002, for the Asian market.

At 9:28am: (LON:NFX) Nuformix Plc share price was 0p at 2.95p